Literature DB >> 24816581

Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.

Hien K Duong1, Bipin N Savani2, Ed Copelan3, Steven Devine4, Luciano J Costa5, John R Wingard6, Paul Shaughnessy7, Navneet Majhail8, Miguel-Angel Perales9, Corey S Cutler10, William Bensinger11, Mark R Litzow12, Mohamad Mohty13, Richard E Champlin14, Helen Leather6, Sergio Giralt9, Paul A Carpenter11.   

Abstract

Peripheral blood progenitor cell mobilization practices vary significantly among institutions. Effective mobilization regimens include growth factor alone, chemotherapy and growth factor combined, and, more recently, incorporation of plerixafor with either approach. Many institutions have developed algorithms to improve stem cell mobilization success rates and cost-effectiveness. However, an optimal stem cell mobilization regimen has not been defined. Practical guidelines are needed to address important clinical questions, including which growth factor is optimal, what chemotherapy and dose is most effective, and when to initiate leukapheresis. We present recommendations, based on a comprehensive review of the literature, from the American Society of Blood and Marrow Transplantation.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hematopoietic transplantation; Peripheral blood; Progenitor cell mobilization

Mesh:

Year:  2014        PMID: 24816581     DOI: 10.1016/j.bbmt.2014.05.003

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  30 in total

1.  Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.

Authors:  Lauren Veltri; Aaron Cumpston; Alexandra Shillingburg; Sijin Wen; Jin Luo; Sonia Leadmon; Kathy Watkins; Michael Craig; Mehdi Hamadani; Abraham S Kanate
Journal:  Cytotherapy       Date:  2015-10-21       Impact factor: 5.414

Review 2.  The evolution of stem-cell transplantation in multiple myeloma.

Authors:  Sarakshi Mahajan; Nidhi Tandon; Shaji Kumar
Journal:  Ther Adv Hematol       Date:  2018-03-05

3.  Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum.

Authors:  Miguel-Angel Perales; William A Wood; Pere Barba; Linda J Burns; Mark R Litzow; Mark B Juckett; Krishna V Komanduri; Stephanie J Lee; Sean M Devlin; Luciano J Costa; Shakila Khan; Andrea King; Andreas Klein; Amrita Krishnan; Adriana Malone; Muhammad Mir; Carina Moravec; George Selby; Vivek Roy; Melissa Cochran; Melisa K Stricherz; Michael D Westmoreland
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-21       Impact factor: 5.742

4.  Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.

Authors:  Laura F Newell; Kelsea M Shoop; Rebekah J Knight; Sara N Murray; Rogelyn P Kwock; Carol E Jacoby; Susan Slater; Bryon E Allen; Casondra Ottowa; Brad Cota; Peggy L Appel; Rachel J Cook; Richard T Maziarz; Gabrielle Meyers
Journal:  Cytotherapy       Date:  2019-05-10       Impact factor: 5.414

Review 5.  Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges.

Authors:  Valentina Ghiaccio; Maxwell Chappell; Stefano Rivella; Laura Breda
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

6.  Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study.

Authors:  Keijiro Sato; Ken Ishiyama; Go Aoki; Hiroyuki Maruyama; Noriaki Tsuji; Mikoto Tanabe; Yoshitaka Zaimoku; Hidehiro Sato; Hirohito Yamazaki; Masaki Yamaguchi; Akiyoshi Takami; Shinji Nakao
Journal:  Int J Hematol       Date:  2019-09-21       Impact factor: 2.490

Review 7.  Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.

Authors:  M Martino; R M Lemoli; C Girmenia; L Castagna; B Bruno; F Cavallo; M Offidani; I Scortechini; M Montanari; G Milone; L Postacchini; A Olivieri
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

Review 8.  Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis.

Authors:  Anastasie M Dunn-Pirio; Benjamin M Heyman; Dan S Kaufman; Revere P Kinkel
Journal:  Curr Treat Options Neurol       Date:  2019-10-17       Impact factor: 3.598

9.  Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.

Authors:  Emily C Liang; Lori S Muffly; Parveen Shiraz; Judith A Shizuru; Laura Johnston; Sally Arai; Matthew J Frank; Wen-Kai Weng; Robert Lowsky; Andrew Rezvani; Everett H Meyer; Robert Negrin; David B Miklos; Surbhi Sidana
Journal:  Transplant Cell Ther       Date:  2021-02-25

10.  Algorithms utilizing peripheral blood hematopoietic progenitor cell counts in lieu of some CD34+ cell counts predict successful peripheral blood stem cell collections with substantial time and cost savings.

Authors:  B W Steussy; M Capper; M D Krasowski; N S Rosenthal; A J Schlueter
Journal:  ISBT Sci Ser       Date:  2016-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.